The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell".
The average consensus recommendation for the pharmaceuticals peer group is "buy".
Wall Street's median 12-month price target for Cellectar Biosciences Inc is $10.00, about 284.6% above its August 12 closing price of $2.60.
CLRB•
